Samsung Bioepis has announced positive results from a post-hoc and subgroup analysis of its recently EU-approved Byooviz (ranibizumab) biosimilar, at the same time as it disclosed the findings of a five-year follow-up study comparing the company’s Ontruzant (trastuzumab) biosimilar in early or locally advanced HER2 positive breast cancer with its reference brand, Herceptin.
From the first analysis, the Korean firm – which scooped an approval from the European Commission for Byooviz last month...